Mutations that collaborate with IL-7Ra signaling pathways to drive ALL

Gisele O.L. Rodrigues,Sarah D. Cramer,Hila Y. Winer,Julie A. Hixon,WenQing Li,José Andres Yunes,Scott K. Durum
DOI: https://doi.org/10.1016/j.jbior.2021.100788
2021-01-01
Advances in Biological Regulation
Abstract:The IL-7 pathway is required for normal T cell development and survival. In recent years the pathway has been shown to be a major driver of acute lymphoblastic leukemia (ALL), the most common cancer in children. Gain-of-function mutations in the alpha chain of the IL-7 receptor found in ALL patients clearly demonstrated that this pathway was a driver. However mutant IL-7R alone was insufficient to transform primary T cell progenitors, indicating that cooperating mutations were required. Here we review evidence for additional oncogenic mutations in the IL-7 pathway. We discuss several oncogenes, loss of tumor suppressor genes and epigenetic effects that can cooperate with mutant IL-7 receptor. These include NRas, HOXA, TLX3, Notch 1, Arf, PHF6, WT1, PRC, PTPN2 and CK2. As new therapeutics targeting the IL-7 pathway are developed, combination with agents directed to cooperating pathways offer hope for novel therapies for ALL.
What problem does this paper attempt to address?